Towards Healthcare
North America Cell and Gene Therapy Market to Rise 24.01% CAGR till 2034

North America Cell and Gene Therapy Market Advanced Therapies Drives Rapid Growth

According to forecasts, the North America cell and gene therapy market will grow from USD 9.19 billion in 2024 to USD 79.01 billion by 2034, with an expected CAGR of 24.01%. The North America cell and gene therapy market is growing due to the rising demand for highly specific therapeutics for genetic disorders.

Content

  • Last Updated: 13 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The North America cell and gene therapy market in 2025 is valued at USD 11.34 billion and is projected to climb to USD 79.01 billion by 2034, with a CAGR of 24.01% over the forecast period.

The U.S. is currently leading the North America cell and gene therapy market due to government support and initiatives taken by organizations such as the FDA.

Some key players include Novartis AG, Bluebird Bio, CRISPR Therapeutics, Bristol Myers Squibb, etc.

Key trends include rising demand for personalized medicine and clinical research for developing cell and gene therapies for rare diseases.

National Institutes of Health, FDA, WHO, CDC.
Any Questions